Curevo rounds up $110M to challenge GSK’s Shringrix, nabs Moncef Slaoui to lead board By Gabrielle Masson Mar 17, 2025 10:44am Curevo Vaccine GSK Moncef Slaoui Shingrix ...

"Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate," said Joseph Payne, President & Chief ...

SAN DIEGO, June 20, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease ...

Arcturus Therapeutics Holdings Inc., a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and ...

NPR's Mary Louise Kelly talks with Philip Zelikow about the forthcoming report "Lessons Learned From Covid War: An Investigative Report" by the Covid Crisis Group.

I reminded Jared that I had made very clear to Moncef Slaoui that we would not take doses from other countries to give to the U.S. and that I had almost begged OWS to increase their ordered ...

Former Operation Warp Speed chief Moncef Slaoui, who GlaxoSmithKline fired last year because of a sexual harassment claim, is returning (PDF) $3.86 million to the company, according to its annual ...

Inside Pfizer’s race to produce the world’s biggest supply of covid vaccine Pfizer engineers used a ‘bulldozer’ approach to go from ‘utter failure’ to 3 billion doses ...

Moncef Slaoui, the former head of Operation Warp Speed, is facing a sexual-harassment allegation. His former employer GlaxoSmithKline said an investigation "substantiated the allegations and is ...

Topline Moncef Slaoui, the leader of the Trump administration’s coronavirus vaccine development program, has stepped down from his new job as the chief scientific officer for Centessa ...

Moncef Slaoui, the former scientific director of COVID-19 vaccine development at Operation Warp Speed during the Trump administration, has been fired from a joint venture of GlaxoSmithKline over ...